Recent submissions

  • A Dosimetric Comparison of Breast Radiotherapy Techniques to Treat Locoregional Lymph Nodes Including the Internal Mammary Chain. 

    Ranger, A; Dunlop, A; Hutchinson, K; Convery, H; Maclennan, MK; Chantler, H; Twyman, N; Rose, C; McQuaid, D; Amos, RA; Griffin, C; deSouza, NM; Donovan, E; Harris, E; Coles, CE; Kirby, A
    AIMS: Radiotherapy target volumes in early breast cancer treatment increasingly include the internal mammary chain (IMC). In order to maximise survival benefits of IMC radiotherapy, doses to the heart and lung should be ...
  • Noninvasive detection of HER2 amplification with plasma DNA digital PCR. 

    Gevensleben, H; Garcia-Murillas, I; Graeser, MK; Schiavon, G; Osin, P; Parton, M; Smith, IE; Ashworth, A; Turner, NC (2013-06)
    PURPOSE: Digital PCR is a highly accurate method of determining DNA concentration. We adapted digital PCR to determine the presence of oncogenic amplification through noninvasive analysis of circulating free plasma DNA and ...
  • Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease. 

    Popat, S; Hearle, N; Hogberg, L; Braegger, CP; O'Donoghue, D; Falth-Magnusson, K; Holmes, GK; Howdle, PD; Jenkins, H; Johnston, S; Kennedy, NP; Kumar, PJ; Logan, RF; Marsh, MN; Mulder, CJ; Torinsson Naluai, A; Sjoberg, K; Stenhammar, L; Walters, JR; Jewell, DP; Houlston, RS (2002-03)
    Susceptibility to coeliac disease involves HLA and non-HLA-linked genes. The CTLA4/CD28 gene region encodes immune regulatory T-cell surface molecules and is a strong candidate as a susceptibility locus. We evaluated ...
  • The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). 

    Leach, MO; Eeles, RA; Turnbull, LW; Dixon, AK; Brown, J; Hoff, RJ; Coulthard, A; Dixon, JM; Easton, DF; Evans, DG; Gilbert, FJ; Hawnaur, J; Hayes, C; Kessar, P; Lakhani, S; Liney, G; Moss, SM; Padhani, AP; Pointon, LJ; Sydenham, M; Walker, LG; Warren, RM; Haites, NE; Morrison, P; Cole, T; Rayter, Z; Donaldson, A; Shere, M; Rankin, J; Goudie, D; Steel, CM; Davidson, R; Chu, C; Ellis, I; Mackay, J; Hodgson, SV; Homfray, T; Douglas, F; Quarrell, OW; Eccles, DM; Gilbert, FG; Crothers, G; Walker, CP; Jones, A; Slack, N; Britton, P; Sheppard, DG; Walsh, J; Whitehouse, G; Teh, W; Rankin, S; Boggis, C; Potterton, J; McLean, L; Gordon, PA; Rubin, C (2002-09)
    The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS) is in progress. The study design, accrual to date, and related research projects are described. Revised accrual rates ...
  • Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. 

    Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Horswell, S; Chambers, T; O'Brien, T; Lopez, JI; Watkins, TBK; Nicol, D; Stares, M; Challacombe, B; Hazell, S; Chandra, A; Mitchell, TJ; Au, L; Eichler-Jonsson, C; Jabbar, F; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Stewart, A; Xing, W; Smith, JC; Escudero, M; Huffman, A; Matthews, N; Elgar, G; Phillimore, B; Costa, M; Begum, S; Ward, S; Salm, M; Boeing, S; Fisher, R; Spain, L; Navas, C; Grönroos, E; Hobor, S; Sharma, S; Aurangzeb, I; Lall, S; Polson, A; Varia, M; Horsfield, C; Fotiadis, N; Pickering, L; Schwarz, RF; Silva, B; Herrero, J; Luscombe, NM; Jamal-Hanjani, M; Rosenthal, R; Birkbak, NJ; Wilson, GA; Pipek, O; Ribli, D; Krzystanek, M; Csabai, I; Szallasi, Z; Gore, M; McGranahan, N; Van Loo, P; Campbell, P; Larkin, J; Swanton, C; TRACERx Renal Consortium (2018-04-19)
    The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ...
  • Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. 

    Turajlic, S; Xu, H; Litchfield, K; Rowan, A; Chambers, T; Lopez, JI; Nicol, D; O'Brien, T; Larkin, J; Horswell, S; Stares, M; Au, L; Jamal-Hanjani, M; Challacombe, B; Chandra, A; Hazell, S; Eichler-Jonsson, C; Soultati, A; Chowdhury, S; Rudman, S; Lynch, J; Fernando, A; Stamp, G; Nye, E; Jabbar, F; Spain, L; Lall, S; Guarch, R; Falzon, M; Proctor, I; Pickering, L; Gore, M; Watkins, TBK; Ward, S; Stewart, A; DiNatale, R; Becerra, MF; Reznik, E; Hsieh, JJ; Richmond, TA; Mayhew, GF; Hill, SM; McNally, CD; Jones, C; Rosenbaum, H; Stanislaw, S; Burgess, DL; Alexander, NR; Swanton, C; PEACE; TRACERx Renal Consortium (2018-04-19)
    Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with ...
  • Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. 

    Lim, KHJ; Spain, L; Barker, C; Georgiou, A; Walls, G; Gore, M; Turajlic, S; Board, R; Larkin, JM; Lorigan, P
    Background: Agreement on the utility of imaging follow-up in patients with high-risk melanoma is lacking. A UK consensus statement recommends a surveillance schedule of CT or positron-emission tomography-CT and MRI brain ...
  • Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. 

    Cooke, R; Jones, ME; Cunningham, D; Falk, SJ; Gilson, D; Hancock, BW; Harris, SJ; Horwich, A; Hoskin, PJ; Illidge, T; Linch, DC; Lister, TA; Lucraft, HH; Radford, JA; Stevens, AM; Syndikus, I; Williams, MV; Swerdlow, AJ
    BACKGROUND: Women treated with supradiaphragmatic radiotherapy (sRT) for Hodgkin lymphoma (HL) at young ages have a substantially increased breast cancer risk. Little is known about how menarcheal and reproductive factors ...
  • Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer. 

    Blok, EJ; Engels, CC; Dekker-Ensink, G; Meershoek-Klein Kranenbarg, E; Putter, H; Smit, VTHBM; Liefers, G-J; Morden, JP; Bliss, JM; Coombes, RC; Bartlett, JMS; Kroep, JR; van de Velde, CJH; Kuppen, PJK (2018-05-15)
    PURPOSE: Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic for disease-free survival and predictive for the benefit of chemotherapy in patients with early breast cancer, but have not been studied for ...
  • KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. 

    Sclafani, F; Chau, I; Cunningham, D; Hahne, JC; Vlachogiannis, G; Eltahir, Z; Lampis, A; Braconi, C; Kalaitzaki, E; De Castro, DG; Wotherspoon, A; Capdevila, J; Glimelius, B; Tarazona, N; Begum, R; Lote, H; Hulkki Wilson, S; Mentrasti, G; Brown, G; Tait, D; Oates, J; Valeri, N (2018-01-23)
    There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples ...
  • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. 

    Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; Gazinska, P; Owen, J; Abraham, J; Barrett, S; Barrett-Lee, P; Brown, R; Chan, S; Dowsett, M; Flanagan, JM; Fox, L; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, MQ; Hoadley, KA; Parikh, J; Parker, P; Perou, CM; Roylance, R; Shah, V; Shaw, A; Smith, IE; Timms, KM; Wardley, AM; Wilson, G; Gillett, C; Lanchbury, JS; Ashworth, A; Rahman, N; Harries, M; Ellis, P; Pinder, SE; Bliss, JM
    Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs ...
  • MENOS4 trial: a multicentre randomised controlled trial (RCT) of a breast care nurse delivered cognitive behavioural therapy (CBT) intervention to reduce the impact of hot flushes in women with breast cancer: Study Protocol. 

    Fenlon, D; Nuttall, J; May, C; Raftery, J; Fields, J; Kirkpatrick, E; Abab, J; Ellis, M; Rose, T; Khambhaita, P; Galanopoulou, A; Maishman, T; Haviland, J; Griffiths, G; Turner, L; Hunter, M (2018-05-08)
    BACKGROUND: Women who have been treated for breast cancer may identify vasomotor symptoms, such as hot flushes and night sweats (HFNS), as a serious problem. HFNS are unpleasant to experience and can have a significant ...
  • Women's Free-text Comments on their Quality of Life: An Exploratory Analysis from the UK Standardisation of Breast Radiotherapy (START) Trials for Early Breast Cancer. 

    Mills, J; Haviland, JS; Moynihan, C; Bliss, JM; Hopwood, P; START Trial Management Group (2018-04-10)
    AIMS: Exploratory analysis of patients' unsolicited written comments in the first 2 years of the Standardisation of Breast Radiotherapy (START) trial quality of life study highlighted a potential effect of non-treatment-related ...
  • The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. 

    Wilson, JM; Dearnaley, DP; Syndikus, I; Khoo, V; Birtle, A; Bloomfield, D; Choudhury, A; Graham, J; Ferguson, C; Malik, Z; Money-Kyrle, J; O'Sullivan, JM; Panades, M; Parker, C; Rimmer, Y; Scrase, C; Staffurth, J; Stockdale, A; Cruickshank, C; Griffin, C; Hall, E; CHHiP Investigators (2018-04-01)
    PURPOSE: Outcome data on radiation therapy for prostate cancer in an elderly population are sparse. The CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer) trial provides ...
  • Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. 

    Wedge, DC; Gundem, G; Mitchell, T; Woodcock, DJ; Martincorena, I; Ghori, M; Zamora, J; Butler, A; Whitaker, H; Kote-Jarai, Z; Alexandrov, LB; Van Loo, P; Massie, CE; Dentro, S; Warren, AY; Verrill, C; Berney, DM; Dennis, N; Merson, S; Hawkins, S; Howat, W; Lu, Y-J; Lambert, A; Kay, J; Kremeyer, B; Karaszi, K; Luxton, H; Camacho, N; Marsden, L; Edwards, S; Matthews, L; Bo, V; Leongamornlert, D; McLaren, S; Ng, A; Yu, Y; Zhang, H; Dadaev, T; Thomas, S; Easton, DF; Ahmed, M; Bancroft, E; Fisher, C; Livni, N; Nicol, D; Tavaré, S; Gill, P; Greenman, C; Khoo, V; Van As, N; Kumar, P; Ogden, C; Cahill, D; Thompson, A; Mayer, E; Rowe, E; Dudderidge, T; Gnanapragasam, V; Shah, NC; Raine, K; Jones, D; Menzies, A; Stebbings, L; Teague, J; Hazell, S; Corbishley, C; CAMCAP Study Group; de Bono, J; Attard, G; Isaacs, W; Visakorpi, T; Fraser, M; Boutros, PC; Bristow, RG; Workman, P; Sander, C; TCGA Consortium; Hamdy, FC; Futreal, A; McDermott, U; Al-Lazikani, B; Lynch, AG; Bova, GS; Foster, CS; Brewer, DS; Neal, DE; Cooper, CS; Eeles, RA (2018-05)
    Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer ...
  • FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment. 

    Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; Manodoro, F; Fenwick, K; Bliss, J; Yarnold, J; Somaiah, N (2018-04-26)
    BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline ...
  • Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial. 

    Yip, K; Melcher, A; Harrington, K; Illidge, T; Nobes, J; Webster, A; Smith, D; Lorigan, P; Nathan, P; Larkin, J (2018-04)
  • Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience. 

    Coleman, N; Michalarea, V; Alken, S; Rihawi, K; Lopez, RP; Tunariu, N; Petruckevitch, A; Molife, LR; Banerji, U; De Bono, JS; Welsh, L; Saran, F; Lopez, J (2018-04-10)
    BACKGROUND: Primary malignant brain tumours (PMBT) constitute less than 2% of all malignancies and carry a dismal prognosis. Treatment options at relapse are limited. First-in-human solid tumour studies have historically ...
  • 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. 

    Iveson, TJ; Kerr, RS; Saunders, MP; Cassidy, J; Hollander, NH; Tabernero, J; Haydon, A; Glimelius, B; Harkin, A; Allan, K; McQueen, J; Scudder, C; Boyd, KA; Briggs, A; Waterston, A; Medley, L; Wilson, C; Ellis, R; Essapen, S; Dhadda, AS; Harrison, M; Falk, S; Raouf, S; Rees, C; Olesen, RK; Propper, D; Bridgewater, J; Azzabi, A; Farrugia, D; Webb, A; Cunningham, D; Hickish, T; Weaver, A; Gollins, S; Wasan, HS; Paul, J (2018-04)
    BACKGROUND: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior ...
  • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

    Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, B; Gillessen, S; Malik, Z; Jones, R; Parker, C; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, D; Hughes, R; McLaren, D; Lester, J; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND (2018-02-26)
    Background: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in STAMPEDE: a multi-arm multi-stage platform randomised controlled ...

View more